Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 315 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ventricular Arrhythmias Clear all

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
Interventions: Catheter ablation; Device
Lead sponsor: Heart Rhythm Clinical and Research Solutions, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more

Conditions: Myocarditis, Premature Ventricular Contractions, Ventricular Tachycardia (VT)
Interventions: Not listed
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Heart Failure, Systolic, Left Ventricular Assist Device, ICD
Interventions: ICD programming; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bradycardia, Heart Failure, Ventricular Dysfunction
Interventions: Ultra High Frequency Electrocardiogram (UHF-ECG); Device
Lead sponsor: VDI Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Avondale, Arizona • Mesa, Arizona • Chicago, Illinois + 4 more

Conditions: Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Not listed
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: Not listed
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Tachycardia, Ventricular
Interventions: CyberHeart System; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 72
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 69 more

Conditions: Ventricular Tachycardia, Arrhythmia
Interventions: 123I-metaiodobenzylguanidine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Arrythmia, Cardiomyopathies
Interventions: Intra-Op Prophylactic VT ablation, Conventional Management; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Sudden Cardiac Death, Ventricular Arrythmias
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Wausau, Wisconsin

Conditions: Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR); Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Ventricular Fibrillation
Interventions: Simulation-Based Training; Behavioral
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Ventricular Arrythmia
Interventions: Ablation using Optrell™ mapping catheter; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy
Interventions: T Wave Alternans Test; Procedure
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: Not listed
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 47
States / cities: Mobile, Alabama • Phoenix, Arizona • Walnut Creek, California + 44 more

Conditions: Premature Ventricular Beats
Interventions: Ranolazine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tachycardia, Ventricular, Catheter Ablation
Interventions: Antiarrhythmic drug; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Failure, Implantable Defibrillator User, Ventricular Arrythmia
Interventions: Not listed
Lead sponsor: Larisa Tereshchenko; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3,471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 2 more

Conditions: Tachycardia, Ventricular
Interventions: Remifentanil; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ventricular Tachycardia
Interventions: Dantrolene/Ryanodex, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Etripamil, Placebo; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more

Search by objective public record fields.

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry

STandardized Ultra-conservative Or Physician-directed ICD Programming for Continuous Flow LVAD Support

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.

CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation

DF4 Connector System Post-Approval Study

Imaging With a Radio Tracer to Guide VT Ablations

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

The Comparative Advantage of the Optrell Mapping Catheter in Ventricular Arrhythmias From the Papillary Muscles

MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients

Study to Reduce Symptoms of Premature Beats With Ranolazine

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Global Electrical Heterogeneity and Clinical Outcomes

Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

Heart Disease in Sickle Cell Anemia

Study of the Wearable Defibrillator in Heart-Failure Patients

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm